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Relations, Tokyo, JapanA B S T R A C TObjective: To provide an overview of how current utility values were
obtained in the cost-utility analysis (CUA) for pharmaceuticals in
Japan on the basis of methodological guidelines developed in England
and Wales, Australia, Canada, France, and Japan by conducting a
systematic review of the published literature. Methods: We searched
and reviewed CUAs conducted for pharmaceuticals in Japan, reporting
the results as cost per quality-adjusted life-year (QALY). The databases
we used were PubMed, EconLit, Centre for Reviews and Dissemination,
and the Japan Medical Abstracts Society. The search terms were
“QALY” and “Japan” or “cost utility” and “Japan” in the PubMed
database, Centre for Reviews and Dissemination, and EconLit. In the
search on the Japan Medical Abstracts Society database, we used the
term “QALY.” Results: In total, 41 CUA articles met the selection
criteria and the most common method of obtaining utility values
was derived from the published literature (31 CUAs, 168 utility values).
Five CUAs were elicited by directly asking the participants regarding
their own health state, and four CUAs used “mapping” techniques inee front matter Copyright & 2014, International S
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.1016/j.vhri.2014.04.011
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awara City, Tochigi 324-8501, Japan.which utility values were linked to clinical results. The most com-
monly used instrument was the EuroQol ﬁve-dimensional question-
naire followed by the time-trade-off. A few CUAs mentioned how they
selected the literature for the utility values, and some utility values
were combined across different sources, using different methods, and
obtained from different locations. Conclusions: Practical methodo-
logical guidelines need to be developed to provide standardized
methods of presenting the procedure of using utility values from the
literature. Although transferability of utility values across jurisdictions
has not been discussed fully, this topic should be covered in meth-
odological guidelines and recommend best practices for evaluations.
Keywords: cost-effectiveness, cost-utility, health-related quality of life,
QALY.
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The concept of cost-effectiveness has been used as a decision-
making criterion for the allocation of scarce resources for health
care in several countries, such as in the United Kingdom,
Australia, and Canada. Cost-utility analysis (CUA) is one of the
major methods used for determining cost-effectiveness, and it
has been used in these countries for more than a decade. Last
year, France composed its own set of cost-effectiveness guide-
lines for use in the pricing of pharmaceuticals. In April 2012,
Japanese government’s consulting body called the Central Social
Insurance Medical Council (Chu-i-kyo) set common ground for
the discussion of the possible introduction of the cost-
effectiveness concept for health technologies, including pharma-
ceuticals. In parallel, a methodological guideline was proposed by
an academic group in early 2013 [1]. After 2 years of deliberations,
Chu-i-kyo now focuses more attention on drugs as cost-
effectiveness evaluation targets, either the newly listed ones or
those with a certain period passed since listing. In addition, fromApril 2014, pharmaceutical companies are being requested to
submit economic evaluations for designated products, as a trial.
To conduct CUAs for pharmaceuticals, a substantial amount of
data is required. This data not only includes clinical data but also
data that are not usually taken from clinical trials, such as long-
time transition. One piece of such necessary data is the utility
values used when calculating quality-adjusted life-years (QALYs).
It was not common to take utility data in clinical trials in Japan;
therefore, CUAs often used utility values that were derived from
the literature, sometimes derived from studies conducted at differ-
ent locations, with different instruments. The transferability of
utility values, however, has not been fully discussed. Although
some analysts have argued that utility scores can be used across
studies, because there were no substantial differences across
jurisdictions [2], others insisted that differences in ethic and
cultural backgrounds might affect perceptions of health [3,4]. Badia
et al. [4] suggested that efforts should be made to obtain local
health state indices, wherever possible, and further cross-national
comparisons of preference values should be conducted.ociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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utility measurement methods or instruments yield different utility
values. This could occur in direct methods, such as the standard
gamble (SG), the time trade-off (TTO), and the rating scale (RS), as
well as in indirect methods, such as the EuroQol Five-Dimension
(EQ-5D) the Health Utilities Index (HUI), and so on. Among the
direct methods, for example, it was reported that for the same
patient, the scores derived from the SG were generally greater than
their scores on the TTO [5–7]. A Japanese study by Noto et al. [8]
reported that the elicited utility scores from students and medical
staff under hypothetical stroke rehabilitation revealed greater
scores on the RS than on the TTO. Similarly, with reference to
indirect methods, Neumann et al. [9] reported that scores of
patients with dementia on the HUI 2 were greater than their scores
on the HUI 3, for all levels of severity. Furthermore, systematic
reviews of 28 empirical studies that compared direct and indirect
methods of estimating utilities revealed that direct methods (SG
and TTO, in this case) resulted in higher scores than indirect
methods (the EQ-5D and HUI 3, in this case) [10].
To review the current practices related to these two issues, we
examine what was addressed in the national methodological
guidelines for economic evaluation across different countries
because these guidelines represent the best practices in economic
evaluation. Thus, we examined the guidelines provided by the
following organizations: the National Institute for Health and
Care Excellence (NICE) in the United Kingdom (England and
Wales) [11], the Pharmaceutical Beneﬁts Advisory Committee in
Australia [12], the Canadian Agency for Drugs and Technologies
in Health in Canada [13], the Haute Autorité de Santé (HAS) in
France [14], and the proposed guideline provided by an academic
group in Japan [1] that was funded by the Japanese Ministry of
Health and Welfare.Methods to Derive Utility Values as Prescribed in the National
Guidelines of Five Countries
Although most of the guidelines prioritized the utility values
derived from the studies conducted in their own county, the
guidelines from all ﬁve countries allowed for the elicitation of
utility values from the literature subject to the fulﬁllment of
certain conditions. For instance, in France, the utility values and
the life-years were recommended to be extracted from French
empirical data. If French data were not available, the use of foreign
data was allowed if the methodological quality of the study was
good (although “good” was not deﬁned) and its external validity
was justiﬁed. The NICE guideline requires the utility values to be
measured directly from the patients using the EQ-5D. If such
information is not available in data from relevant clinical trials,
it recommends the use of EQ-5D data from the literature, provided
it is identiﬁed using a systematic and transparent method and
there is clear explanation of the justiﬁcation for choosing a
particular data set. The Australian guideline recognized that utility
estimates might sometimes be derived from the literature. It
speciﬁes, however, that the details of the methods used to identify
the studies and to elicit the utility estimate should be presented
clearly, so that validity should be assessed. According to the
Canadian guideline, if utility values (preference scores) were not
measured in a prospective study, they could be sourced from the
literature if they are appropriate for the population of interest. In
the proposed Japanese guideline, it is recommended that utility
values be, in principle, elicited from the public. If Japanese studies,
however, are not of optimal quality, the use of study results from
other country settings is allowed.
Situations in which more than one plausible set of utility data
for a health state was available from the literature, the guidelines
from the ﬁve countries differed on their recommendations. The
NICE and HAS guidelines recommended that scores from a singlesource should be used and sensitivity analyses should be con-
ducted to show the effect of the alternative utility values. The
Australian guidelines provide a warning that combining utility
weights across different sources, for different health states,
makes it difﬁcult to interpret the results, particularly across those
using different methods. We also noted that this issue was not
addressed by the Canadian and Japanese guidelines.Measuring Utility Values as Prescribed in the National
Guidelines of Five Countries
Recognizing the variation in the utility values depending on the
instrument, the NICE guideline applied strict criteria by specifying
that only the EQ-5D measurement scale should be used for utility
measurements. We also found that the recommendations in the
guidelines may be inﬂuenced by the availability of the instruments
in the country. For instance, the French authority recommended
the use of “validated preference-based scores available in France”;
currently, only the EQ-5D and HUI 3 meet this criterion. The
proposed Japanese guideline recommended the use of index-type
instruments with a newly developed Japanese scoring algorithm,
which is currently met by the EQ-5D. The Canadian guidelines are
relatively ﬂexible and encouraged using indirect methods, such as
HUI, the EQ-5D, the Short Form 6 Dimension (derived from the
MOS 36-Item Short-Form Health Survey), and the 15D because they
are easy to obtain, compare, and interpret. The guidelines,
however, recommended that analysts select in advance the most
appropriate instrument for the condition, one that best suits the
study question and that prevents bias. The Australian guidelines
are realistic in this regard and do not specify any particular
instrument because such instruments were not always used in
all the trials. The guidelines generally preferred, however, the
indirect methods of multiattribute utility instruments. Although
the ﬁve guidelines varied in terms of the instruments used to
measure the utility values, all guidelines recommended at least the
EQ-5D.
Considering these issues surrounding utility values, the objec-
tive of this study was to provide an overview of how current
utility values were obtained in CUAs for pharmaceuticals in Japan
on the basis of recommendations in these ﬁve methodological
guidelines. If the values were elicited from the literature, we
examined the original sources (original study or not/study loca-
tion/instrument used), the criteria and methods used to choose
those selected original sources, and if more than one plausible set
of utility data was available, methods of dealing with or selecting
the data. We accomplished these objectives by conducting a
systematic review of the published literature on CUAs for phar-
maceuticals in Japan.Methods
Literature Review
We searched the published literature on the CUAs conducted in
Japan that reported the results as cost per QALY. The following
databases were used for this search: PubMed, Centre for Reviews
and Dissemination (CRD) in the University of York, EconLit, and
the Japan Medical Abstracts Society (Ichushi). We included all
articles that ﬁt the search criteria, irrespective of the language of
publication. The search terms used for the PubMed, EconLit, and
CRD databases were “QALY” and “Japan,” or “cost utility” and
“Japan.” For the Ichushi database, we used “QALY” as the search
term. We conducted the search on February 20, 2013, and the
search period was not speciﬁed. We also searched reference lists
of the included studies.
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Because we were interested in the process of evaluating the cost-
effectiveness of individual drugs, we only included those studies
that targeted drugs. The comparators, the items compared with
the target drug, however, could be any health care technologies,
such as therapeutic and/or diagnostic techniques, and medical
devices, as well as drugs.
Reviews, commentaries, or educational articles were excluded.
We excluded one study that collected only utility values, without
compiling the cost per QALY. With reference to CUAs that targeted
drugs, we also excluded the studies that compared a pharmaceut-
ical agent in different regulatory situations, because current dis-
cussions in the Chu-i-kyo focus on drugs and explore their cost-
effectiveness assessment for using such information to determine
either the reimbursement status or the list price of some pharma-
ceuticals. Therefore, comparisons such as prescription drugs versus
those in the over-the-counter setting, or branded versus generic
versions of the same agents, were excluded. Studies comparing the
same agents across a number of different regimens were also
excluded for the same reason. We also excluded pharmaceutical
agents that are not covered by social health insurance in Japan,
such as prophylactic agents for healthy people (e.g., vaccines),
because these were irrelevant to the current interest.
Items of the Review
When the published CUA studies were extracted on the basis of
inclusion and exclusion criteria, the following research questions
were addressed:1. How did the CUAs obtain their utility values (empirical study/
literature/others)? If the values were elicited from the literature,124 arcles idenﬁed through PubMed search
PubMed search
34 arcles remained aer applied the inclusion/exclusion 
criteria.
41 arcles (CUAs) remained a
2
1
1
a
52 arcles excluded due to non 
relevant intervenon; diagnosc 
tesng, rehabilitaons, and surgical 
intervenons etc. evaluated.
6 arcles excluded due to non 
relevant intervenon; vaccines 
evaluated.
31 arcles excluded due to non 
relevant study type; review, 
commentary and/or educaonal 
arcles, and studies not completed as 
CUA.
1 arcle excluded due to non 
relevant comparators; the same 
agents with the target. 
Inclusion/exclusion criteria applied
Fig. 1 – Disposition of publication identiﬁed for this syste2.er 
0 ar
61 a
8 ar
rcl
mWhat kind of studies were the original sources (original study
or not/study location/instrument used)?3. How were those original sources selected?
4. If more than one plausible set of utility data was available,
how did the author deal with or select those data?
Results
Overall, 124 articles were obtained from the PubMed database,
and 90 articles were excluded on the basis of exclusion criteria.
Similarly, 161 articles were obtained from the Ichushi database,
and 141 articles were excluded according to the exclusion criteria.
In addition, two Japanese articles, Tanno et al. [15,16], were
excluded because these two articles were Japanese versions of
their previous English article Tanno et al. [17]. Finally, after
excluding 11 duplicate articles, 41 CUA articles [17–57] that met
the selection criteria were chosen (Fig. 1). No additional articles
were found in the EconLit and CRD databases.
Methods of Obtaining Utility Values in the 41 CUA Articles
(From Empirical Studies/Literature/Others)
We found that the most common method of obtaining utility
values in the 41 CUA articles [17–57] was deriving them from
published reports (31 CUAs). The remaining ﬁve CUAs elicited
them by directly asking participants to evaluate their own health
state, four CUAs used a “mapping” technique in which utility
values were linked to clinical results, and one CUA assigned
arbitrary values (Table 1).
If the values were elicited from the literature, what kind of
study were the original sources (original study or not/study
location/instrument used)?Ichushi search
11 duplicates removed.
cles remained aer applied the inclusion/exclusion criteria.
rcles idenﬁed through Ichushi search
cles remained aer removed contents duplicaon 
es.
42 arcles excluded due to non 
relevant intervenon; diagnosc 
tesng, rehabilitaons, and surgical 
intervenons etc. evaluated.
9 arcles excluded due to non 
relevant intervenon; vaccines 
evaluated.
89 arcles excluded due to non 
relevant study type; review, 
commentary and/or educaonal 
arcles, and studies not completed as 
CUA.
1 arcle excluded due to non 
relevant comparators; the same 
agents with the target. 
Inclusion/exclusion criteria applied
2 Japanese arcles excluded due to 
contents duplicaon to the same 
author's previous English arcle.
atic literature review. CUA, cost-utility analysis.
Table 1 – Methods of obtaining utility values in 41 CUAs.
Type of utility source Number of
CUA articles
References Number of utility values
used in the articles
Derived from the published literature 31 [18,20–25,28–31,33–41,44,47–54,56,57] 168
Elicited by directly asking participants 5 [19,27,42,45,55] 34
Mapped from clinical results 4 [17,26,32,46] –
Assigned any arbitrary numbers 1 43 5
Total 41 207
CUA, cost-utility analysis.
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of the type of quoted studies from which the utility values were
derived (Table 2). We found that 107 utility values were derived
from original studies that measured the utility values from
samples, and 7 utility values were arbitrary numbers. Further-
more, 54 utility values were derived from either review articles,
including guidelines [34,36,49,50,52], other economic evaluations
irrelevant to the authors [20,23,33,41,51], or communications with
experts and results from other studies [56].
With reference to the study locations, out of the 107 utility values
derived from original studies, 49 utility values were from studies
conducted in Japan, 51 utility values were from studies conducted in
other countries, and 7 utility values were derived by combining
results from studies conducted in Japan and other countries (Table 3).
Regarding the instruments measuring utility values, the most
commonly used instrument was the EQ-5D, and 39 utility values, in
the original studies, were measured using this tool. Furthermore, the
TTO was used to measure 15 of the utility values derived in the
sample. The remaining instruments used for measuring the utility
values were HUI 3 (7 utility values), mapping (7), visual analogue scale
(VAS) (4), HUI 2 (3), the Quality of Well-Being Scale (3), RS (3), SG (3),
MOS 36-Item Short-Form Health Survey (converted to Short Form 6
Dimension) (2). Twenty-one utility values were derived by combining
different sources in the original studies. As presented in Table 2, we
were unable to evaluate how the utility values were measured for 54
utility values, because those values were not derived from the original
studies. Asmentioned before, these values were derived from sources
such as review articles, other economic evaluations, or a combination
of expert opinion and results from other studies. Including the seven
utility values that were arbitrarily assigned numbers, all instruments
measuring the utility values in the 31 CUAs are illustrated in Table 4.
Methods of Selecting and Dealing with Original Sources
Only a few CUAs explained their methods of selecting the studies
for the utility values. Some studies quoted reasons such as the
absence of such data in Japan.
If more than one set of utility data was available, how did the
author deal with or select those data?Table 2 – Study types of cited literature for utility values
Types of cited literature providing utility values
Original studies
Review articles, other economic evaluations, or combination with
expert opinion and results from other studies
No literature (assigned arbitrary numbers)
Total
CUA, cost-utility analysis.
* Duplicated.As illustrated in Table 4, six CUAs ﬁt this situation. The 21
utility values in those studies were obtained by combining the
utility weights across original studies from different sources. In
two cases, two types of instruments were used in one original
study (the EQ-5D and VAS [39], and TTO and SG [25]); however,
the former article did not mention which results were used and
why, while the latter article assigned approximate values by
using both the results. In another case, the original study
measured the health state using the EQ-5D, TTO, SG, and VAS.
The author of the original study [58] determined the mean of the
scores from the TTO and VAS (converted 0 to 1) as the most
appropriate utility; thus, two CUAs [37,40] used the mean. In one
other case, there was more than one data set of utility values for
each utility value, but the ways of selection were not mentioned
by the author [24,29].Discussion
This study provided an overview of how utility values were being
obtained in CUAs for pharmaceuticals in Japan, evaluated with
reference to the national methodological guidelines from ﬁve
countries. The guidelines that we used were NICE in the United
Kingdom (England and Wales) [11], Pharmaceutical Beneﬁts
Advisory Committee in Australia [12], and Canadian Agency for
Drugs and Technologies in Health in Canada [13], which have a
long-term history in cost-effectiveness evaluations, and newly
developed guidelines provided by HAS in France [14] and the
proposed guideline provided by an academic group in Japan [1]. In
Japan, economic evaluation has not yet been ofﬁcially used for
decision making of pricing or reimbursement policy; therefore,
the published literature is not directly linked to the assessment.
We have illustrated, however, the current Japanese health eco-
nomic studies at a glance.
All ﬁve guidelines allowed for deriving utility values from the
literature, subject to systematic and transparent methods of
identifying data and/or ensuring the quality of the study. Among
the 41 CUAs, however, very few studies met these conditions.
Furthermore, most of the CUAs did not explain the source of thein 31 CUAs.
Number of utility values
used in the articles
References
107 [18,21,22,24,25,28–31,33–35,37–
40,44,47–49,53,54,56,57]
54 [20,23,33*,34*,36,41,49*,50–52,56*]
7 [21*,24*,31*]
168
Table 3 – Study locations of the original studies.
Study locations Number of
utility values
References
Japan 49 [18,21,24,25,29,37,40,
47–49,54]
The other countries 51 [21,22,28,30,31,33–
35,
38,39,44,47,53,56,57]
Combining the
utility data from
several locations
7 [24,29]
Total 107
Table 4 – Instruments to measure utility values in
31 CUAs.
Type of utility
values instrument
Number of
utility values
Reference
EQ-5D 39 [18,21,22,24,28,29,31,
37,40,49]
TTO 15 [21,22,33,44,48]
HUI3 7 [30,35,54]
Mapping 7 [47]
VAS 4 [34]
HUI2 3 [57]
QWB 3 [53]
RS 3 [47]
SG 3 [38,56]
SF-36 (SF-6D) 2 [24,29]
Combining utility
weights across
different sources
21 [24,25,29,37,39,40]
Unknown* 54 [20,23,33,34,36,41,49–
52,56]
Assigned arbitrary
numbers
7 [21,24,31]
Total 168
EQ-5D, EuroQol Five-Dimension; HUI, Health Utilities Index; QWB,
Quality of Well-Being Scale; RS, rating scale; SF-6D, Short Form 6
Dimension (derived from SF-36); SF-36, MOS 36-Item Short-Form
Health Survey; SG, standard gamble; TTO, time trade-off; VAS,
visual analogue scale.
* Quoted from either review articles, other economic evaluations,
or combination with expert opinion and results from other
studies.
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utility data was available for one health state, the NICE and
French guidelines recommended that scores from a single source
should be used. In the present study, however, we found that 21
utility values in six CUAs [24,25,29,37,39,40] had been derived by
combining the utility weights across different original studies,
and the methods used for the same varied across these studies. In
addition, ﬁve CUAs [20,23,33,41,51] quoted utility values from
other economic evaluations, which required additional effort to
identify the original study that measured the utility values, which
was sometimes difﬁcult to accomplish because the original article
was too old or the study may not have cited the original studies
appropriately. Therefore, we suggest that guidelines need to be
developed to recommend standardized methods of presenting
and assessing the procedure of using utility values from the
literature. Regarding review articles as the reference for utility
values, we did not focus on them in the present study, because
we classiﬁed all CUAs on the basis of whether the original study
measured the utility values. We acknowledge, however, that it
may be an ideal way to derive utility values because the process
of identifying the data is usually explained. It cases in which it
may not be easy to identify the quoted data in the articles,
authors are recommended to provide more information when
utility values are derived from review articles.
Finally, even if the details of each of the cited utility values
were explained, and the processes to identify those values were
systematic and transparent, transferability of the utility values
remains a vital question that needs to be addressed. Can the
utility values derived from different sources, with different
instruments, be used in the same CUA? For instance, within
one CUA [21], some utility values were derived from a Japanese
study conducted by using the TTO, while other utility values were
derived from the other study conducted on samples from other
countries using the EQ-5D. As described in the Introduction, such
ways of transferring utility values across jurisdictions have not
been fully discussed, but this topic needs to be covered in the
methodological guidelines and relevant best practices need to be
provided for conducting such evaluations.
In the present study, we could not fully assess the method-
ologies of utility value measurements in CUAs in which the utility
values were elicited by asking patients [19,27,42,45,55] and using
mapping techniques [17,26,32,46]. In former CUAs, the most
commonly used instruments were the EQ-5D [19,27,42], followed
by the TTO [55], and a combination of the TTO and SG [45]. These
studies used a sample that ranged from 6 patients to 763 patients
[19,27,42,55] and used health care professionals as proxies [45]. In
terms of using mapping techniques, the guidelines of the ﬁve
countries are described as follows: France does not recommend
the use of mapping techniques in case analysis in their current
state of development. If data from the EQ-5D were not available,NICE guidelines allowed using mapping techniques to estimate
the EQ-5D questionnaire scores from other values observed in
clinical trials. In Canada, if health-related quality of life was not
measured in a prospective study, it is recommended that “pref-
erence scores can be gathered retrospectively through a separate
exercise and then mapped onto the outcomes of the efﬁcacy-
effectiveness trial.” Australian guidelines do not seem to encour-
age mapping because the procedures were not well established,
and they warn that special attention is required when mapping is
presented. Finally, in Japan, using mapping techniques to esti-
mate utility values from patient-reported outcomes is accepted.Recommendations
Reﬂecting the preferences of the local population (in this case, the
Japanese population) is ideal; however, in the real world, per-
forming an empirical study to derive the utility values of the local
area for every CUA would be a challenge. So how utility values
should be extracted from the literature while ensuring the
plausibility and validity of the studies? On the one hand, if utility
values obtained from the literature do not signiﬁcantly affect
results in terms of cost-effectiveness, measuring utility as accu-
rately as possible becomes less important, such that utility values
can just represent health status “off-the-shelf.” If validated utility
catalogs were prepared in appropriate disease areas, more
researchers would be encouraged to perform CUAs. In addition,
in some disease areas, changes in utility values may not have a
signiﬁcant effect on results; therefore, further research is needed
to determine which disease areas are more affected by changes in
utility values.
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A systematic review of the published literature was conducted,
and 41 CUAs met the selection criteria. We found that more than
80% (168 out of 207) of the utility values were derived from
published studies. Among the utility values derived from original
sources, about half the values were obtained from studies con-
ducted overseas and the EQ-5D was the most commonly used
instrument for measuring utility in CUA studies. Only a few CUAs
mentioned how they selected a study for utility values, and 21
utility values were reportedly derived by combining different
sources, using different methods, and obtained from different
locations. The other utility values were elicited from economic
evaluations, which required additional effort to identify the
original study. Therefore, practical methodological guidelines
need to be developed, which recommend standardized methods
of presenting and assessing the procedure of using utility values
from the literature. In addition, although the transferability of
utility values across jurisdictions has not fully been discussed,
this topic should be covered in methodological guidelines and
relevant best practices should be recommended for conducting
such evaluations.
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